Literature DB >> 22267010

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

Ben-Quan Shen1, Keyang Xu, Luna Liu, Helga Raab, Sunil Bhakta, Margaret Kenrick, Kathryn L Parsons-Reponte, Janet Tien, Shang-Fan Yu, Elaine Mai, Dongwei Li, Jay Tibbitts, Jakub Baudys, Ola M Saad, Suzie J Scales, Paul J McDonald, Philip E Hass, Charles Eigenbrot, Trung Nguyen, Willy A Solis, Reina N Fuji, Kelly M Flagella, Darshana Patel, Susan D Spencer, Leslie A Khawli, Allen Ebens, Wai Lee Wong, Richard Vandlen, Surinder Kaur, Mark X Sliwkowski, Richard H Scheller, Paul Polakis, Jagath R Junutula.   

Abstract

The reactive thiol in cysteine is used for coupling maleimide linkers in the generation of antibody conjugates. To assess the impact of the conjugation site, we engineered cysteines into a therapeutic HER2/neu antibody at three sites differing in solvent accessibility and local charge. The highly solvent-accessible site rapidly lost conjugated thiol-reactive linkers in plasma owing to maleimide exchange with reactive thiols in albumin, free cysteine or glutathione. In contrast, a partially accessible site with a positively charged environment promoted hydrolysis of the succinimide ring in the linker, thereby preventing this exchange reaction. The site with partial solvent-accessibility and neutral charge displayed both properties. In a mouse mammary tumor model, the stability and therapeutic activity of the antibody conjugate were affected positively by succinimide ring hydrolysis and negatively by maleimide exchange with thiol-reactive constituents in plasma. Thus, the chemical and structural dynamics of the conjugation site can influence antibody conjugate performance by modulating the stability of the antibody-linker interface.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22267010     DOI: 10.1038/nbt.2108

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  24 in total

1.  Therapeutic antibody fragments with prolonged in vivo half-lives.

Authors:  A P Chapman; P Antoniw; M Spitali; S West; S Stephens; D J King
Journal:  Nat Biotechnol       Date:  1999-08       Impact factor: 54.908

2.  Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.

Authors:  Andrew G Polson; Jill Calemine-Fenaux; Pamela Chan; Wesley Chang; Erin Christensen; Suzanna Clark; Frederic J de Sauvage; Dan Eaton; Kristi Elkins; J Michael Elliott; Gretchen Frantz; Reina N Fuji; Alane Gray; Kristin Harden; Gladys S Ingle; Noelyn M Kljavin; Hartmut Koeppen; Christopher Nelson; Saileta Prabhu; Helga Raab; Sarajane Ross; Dion S Slaga; Jean-Philippe Stephan; Suzie J Scales; Susan D Spencer; Richard Vandlen; Bernd Wranik; Shang-Fan Yu; Bing Zheng; Allen Ebens
Journal:  Cancer Res       Date:  2009-03-03       Impact factor: 12.701

3.  Kinetics and mechanism of the alkaline hydrolysis of maleimide.

Authors:  M N Khan
Journal:  J Pharm Sci       Date:  1984-12       Impact factor: 3.534

4.  Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.

Authors:  Jagath R Junutula; Kelly M Flagella; Richard A Graham; Kathryn L Parsons; Edward Ha; Helga Raab; Sunil Bhakta; Trung Nguyen; Debra L Dugger; Guangmin Li; Elaine Mai; Gail D Lewis Phillips; Hajime Hiraragi; Reina N Fuji; Jay Tibbitts; Richard Vandlen; Susan D Spencer; Richard H Scheller; Paul Polakis; Mark X Sliwkowski
Journal:  Clin Cancer Res       Date:  2010-08-30       Impact factor: 12.531

5.  Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.

Authors:  Cary D Austin; Ann M De Mazière; Paul I Pisacane; Suzanne M van Dijk; Charles Eigenbrot; Mark X Sliwkowski; Judith Klumperman; Richard H Scheller
Journal:  Mol Biol Cell       Date:  2004-09-22       Impact factor: 4.138

6.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Authors:  Svetlana O Doronina; Brian E Toki; Michael Y Torgov; Brian A Mendelsohn; Charles G Cerveny; Dana F Chace; Ron L DeBlanc; R Patrick Gearing; Tim D Bovee; Clay B Siegall; Joseph A Francisco; Alan F Wahl; Damon L Meyer; Peter D Senter
Journal:  Nat Biotechnol       Date:  2003-06-01       Impact factor: 54.908

7.  Catalysis of imido group hydrolysis in a maleimide conjugate.

Authors:  Jeet Kalia; Ronald T Raines
Journal:  Bioorg Med Chem Lett       Date:  2007-09-07       Impact factor: 2.823

8.  Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models.

Authors:  Youjun Chen; Suzanna Clark; Terence Wong; Yongmei Chen; Yvonne Chen; Mark S Dennis; Elizabeth Luis; Fiona Zhong; Sheila Bheddah; Hartmut Koeppen; Alvin Gogineni; Sarajane Ross; Paul Polakis; William Mallet
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

9.  Contribution of linker stability to the activities of anticancer immunoconjugates.

Authors:  Stephen C Alley; Dennis R Benjamin; Scott C Jeffrey; Nicole M Okeley; Damon L Meyer; Russell J Sanderson; Peter D Senter
Journal:  Bioconjug Chem       Date:  2008-03-04       Impact factor: 4.774

10.  Reversibility of covalent electrophile-protein adducts and chemical toxicity.

Authors:  De Lin; Samir Saleh; Daniel C Liebler
Journal:  Chem Res Toxicol       Date:  2008-12       Impact factor: 3.739

View more
  222 in total

1.  A noncanonical function of sortase enables site-specific conjugation of small molecules to lysine residues in proteins.

Authors:  Joseph J Bellucci; Jayanta Bhattacharyya; Ashutosh Chilkoti
Journal:  Angew Chem Int Ed Engl       Date:  2014-10-31       Impact factor: 15.336

Review 2.  Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence.

Authors:  Alyssa B Chinen; Chenxia M Guan; Jennifer R Ferrer; Stacey N Barnaby; Timothy J Merkel; Chad A Mirkin
Journal:  Chem Rev       Date:  2015-08-27       Impact factor: 60.622

3.  Site-selective protein-modification chemistry for basic biology and drug development.

Authors:  Nikolaus Krall; Filipa P da Cruz; Omar Boutureira; Gonçalo J L Bernardes
Journal:  Nat Chem       Date:  2015-11-30       Impact factor: 24.427

4.  Recent advances in the construction of antibody-drug conjugates.

Authors:  Vijay Chudasama; Antoine Maruani; Stephen Caddick
Journal:  Nat Chem       Date:  2016-01-04       Impact factor: 24.427

5.  Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading.

Authors:  Pavel Strop; Kathy Delaria; Davide Foletti; Jody Melton Witt; Adela Hasa-Moreno; Kris Poulsen; Meritxell Galindo Casas; Magdalena Dorywalska; Santiago Farias; Ariel Pios; Victor Lui; Russell Dushin; Dahui Zhou; Thayalan Navaratnam; Thomas-Toan Tran; Janette Sutton; Kevin C Lindquist; Bora Han; Shu-Hui Liu; David L Shelton; Jaume Pons; Arvind Rajpal
Journal:  Nat Biotechnol       Date:  2015-07       Impact factor: 54.908

Review 6.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

Review 7.  Arylation Chemistry for Bioconjugation.

Authors:  Chi Zhang; Ekaterina V Vinogradova; Alexander M Spokoyny; Stephen L Buchwald; Bradley L Pentelute
Journal:  Angew Chem Int Ed Engl       Date:  2019-02-15       Impact factor: 15.336

Review 8.  Improving theranostics in pancreatic cancer.

Authors:  Jeremy King; Michael Bouvet; Gagandeep Singh; John Williams
Journal:  J Surg Oncol       Date:  2017-05-17       Impact factor: 3.454

9.  An arsenical-maleimide for the generation of new targeted biochemical reagents.

Authors:  Aparna Sapra; Colin Thorpe
Journal:  J Am Chem Soc       Date:  2013-02-08       Impact factor: 15.419

10.  Human Serum Albumin Domain I Fusion Protein for Antibody Conjugation.

Authors:  James T Patterson; Henry D Wilson; Shigehiro Asano; Napon Nilchan; Roberta P Fuller; William R Roush; Christoph Rader; Carlos F Barbas
Journal:  Bioconjug Chem       Date:  2016-09-26       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.